Related Experiment Video
Updated: Feb 4, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V
Amy E Armstrong1, David O Walterhouse1,2, Patrick J Leavey3
1Division of Hematology, Oncology, and Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Abstract:
Outcome for patients with metastatic or recurrent/refractory osteosarcoma remains poor. Responses to sorafenib, a multikinase inhibitor, have been seen in recurrent/refractory osteosarcoma, although specific biomarkers of response have not been described. We report a partial response in a 7-year-old with refractory osteosarcoma treated with sorafenib 200 mg twice daily. Toxicities included Common Terminology Criteria for Adverse Events Grade 2 skin toxicities and growth suppression. After 51 months of therapy, he suffered a recurrence. Tumor sequencing later revealed a PDGFRA D846V mutation that was not identified in the relapse specimen. This case demonstrates prolonged partial response to sorafenib and provides a potential biomarker for response.
Insights
A young patient with refractory osteosarcoma experienced a prolonged partial response to sorafenib treatment. Tumor sequencing identified a PDGFRA D846V mutation, suggesting a potential biomarker for sorafenib efficacy in osteosarcoma.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Metastatic or recurrent/refractory osteosarcoma has a poor prognosis.
- Sorafenib, a multikinase inhibitor, has shown some efficacy in osteosarcoma, but response biomarkers are lacking.
Observation:
- A 7-year-old patient with refractory osteosarcoma was treated with sorafenib (200 mg twice daily).
- The patient achieved a partial response lasting 51 months, with toxicities including Grade 2 skin issues and growth suppression.
- Recurrence occurred after 51 months of therapy.
Findings:
- Tumor sequencing of the initial specimen revealed a PDGFRA D846V mutation.
- This mutation was not present in the relapse specimen.
- The PDGFRA D846V mutation is proposed as a potential biomarker for sorafenib response.
Implications:
- This case highlights the potential for prolonged benefit from sorafenib in select osteosarcoma patients.
- The PDGFRA D846V mutation may guide targeted therapy selection for refractory osteosarcoma.
- Further research is warranted to validate PDGFRA D846V as a predictive biomarker for sorafenib treatment.
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Somatic Spinal Reflexes
One of the most well-known somatic spinal reflexes is the stretch reflex, which is activated by the sudden stretching of a muscle. This reflex involves the activation of specialized sensory receptors called muscle spindles, which are located in the muscle tissue and detect changes in the length and speed of muscle contractions. When a muscle is suddenly...

